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THE ability of the enzyme l-asparaginase to inhibit the growth of certain
rodent tumours has been extensively studied and the subject has been recently
reviewed (Old, Boyse and Campbell, 1968; Broome, 1968a). Preliminary clinical
trials (Dolowy et al., 1967; Hill et al., 1968; Oettgen et al., 1968) indicate that it
may be of value in some cases of human leukaemia, but its further evaluation is
limited by the difficulty of extraction and preparation in a form suitable for
therapeutic use.
The activity of l-asparaginase derived from E. coli has been shown to be
enhanced in vitro by the addition of human and animal sera (Lee and Bridges,
1968). In this paper we report on the effect of the addition of human serum
and its fractions on the tumour inhibiting property of l-asparaginase in vivo.
MATERIALS AND METHODS
The assay of asparaginase was as previously described (Lee and Bridges, 1968)
being based on that of Meister (1955). One unit of activity is that quantity of
enzyme which releases 1 ,amole of ammonia from l-asparagine per hour at the
maximum rate.
The leukaemia used in this study, EARADI (Old, Boyse and Stockert, 1965),
was induced by X-radiation in (C57BL/6XA)F1 female mice and carried by us
during the time of these experiments in transplant generations No. 137-156.
Parent mice and hybrids were obtained from Jackson Laboratories. Spinner
Modified Eagle's medium (Flow Laboratories) made 10% with horse serum was
used for the suspension of cells during transplantation.
Pooled guinea pig serum from Dunkin Hartley guinea pigs was obtained by
cardiac puncture and stored, without preservative, at -20° C. (Stayne
Laboratories). The asparaginase activity was in the range 106-157 units per ml.
The E. coli asparaginase used throughout the experiments was from a single
batch of specific activity, 100 i.u./mg. of protein, obtained as a gift from the
Wadley Research Institute, Dallas.
Human serum from normal subjects, Group 0+, was pooled and stored at
-20° C. for up to six weeks without preservative. Freeze dried human plasma
fractions (Baxter Hyland Laboratories) were reconstituted with normal saline.
EXPERIMENTAL METHOD
Tumour cells from mice inoculated intraperitoneally some 10 days previously
were aseptically harvested in Eagle's medium. Mice, in groups of 3, were
inoculated subcutaneously with 1 x 106 tumour cells under an area of shaved370 MAUREEN B. LEE, ROSALIE M. NIBLOCK AND J. M. BRIDGES
skin. They received graded doses ofguinea pig serum, equivalent to 40, 120 and
240 units, or E. coli asparaginase (300, 1000 and 2000 units), either alone or with
1 ml. of human serum added. Control animals received 1 ml. of Eagle's medium
or 1 ml. of human serum only. These regimes were given either at the time of
implantation of cells, or 7 days later when the tumour was well established, at
which time the mean diameter was 7-8 mm. In experiments involving plasma
fractions 1 dose ofE. coli asparaginase (300 units) was used and the regime given
only at the same time as the inoculation of the tumour cells.
To assess tumour growth, tumour diameter was measured in 3 directions and
the mean taken. This observation was made daily following the occurrence of a
palpable tumour. The intervals in days between inoculation of cells, occurrence
of tumour and death were noted.
RESULTS
Inthose mice given 1 ml. ofEagle's medium, tumourswerepalpable after6days
and death occurred after 15 days, at which time the mean diameter ofthe tumour
was 22 mm. (Fig. 1). If 40, 120 or 240 units of guinea pig serum asparaginase
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FIG. 1.-Tumour growth of 1 x 106 EARAD/1 cells 0 --- 0 given 1 ml. ofEagle's]
medium or * * 1 ml. of human serum only.
were given, the intervals before the occurrence of the tumour were 6, 10 and 16
days respectively and death occurred at 18, 23 and 33 days; the rate of tumour
growth and the ultimate size were not altered. This is shown for one animal
given 120 units in Fig. 2. Identical doses of guinea pig serum asparaginase,
given when the tumour was well established, caused temporary slight regression
but the interval to death was not altered, being 18, 16 and 19 days respectively,
as compared with those animals given only Eagle's medium, which died at 15 days
(Fig. 3). If 1 ml. of human serum was added to the various doses of guinea pig
serum, given eitherwiththetumour cells orlater, no difference in tumourinhibitionANTI-TUMOUR ACTIVITY OF TWO ASPARAGINASES 371
20 18
E16 / t
14
E
12
10
0
4
2
0'. O 7 6 / 8 Y 11.I II 12 11 14 I. 16 17 id li 2o 2 2
DAYS AFTER INOCULATION OF TUMOUR CELLS
FIG. 2.-Tumour growth of 1 x 106 EARAD/1 cells after administration of 120 units G.P.S.
asparaginase at time of inoculation, 0 - - - 0 alone or * * with 1 ml. of human
serum added.
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FIG. 3.-Tumour growth of 1 x 106 EARAD/1 cells after administration of 120 units G.P.S.
asparaginase on day 7 0 --- 0 alone, or * *with 1 ml. of human serum added.
was observed (Table I). Animals given 1 ml. of human serum showed the same
pattern of results as those given only Eagle's medium.
E. coli asparaginase was used in doses of 300, 1000 and 2000 units. When
these were given at the time ofthe inoculation ofcells it was only with the largest
dose that the interval to the occurrence of a palpable tumour was altered, being
9 days, whereas with the controls and those given lower doses it was 6 days
(Table II). Once the tumour became established the rate ofgrowth in all groups
was similar and atdeath thetumours werethe samesize. Alterationoftheinterval
until death was seen only with the largest dose, being 23 days, compared with
18 days in the controls and 19 and 21 days in the animals given lower doses of
asparaginase.372 MAUREEN B. LEE, ROSALIE M. NIBLOCK AND J. M. BRIDGES
Treatment
1 ml. Eagle's medium .
1 ml. human serum
G.P.S. 40 units
G.P.S. + human serum
G.P.S. 120 units .
G.P.S. + human serum
G.P.S. 240 units .
G.P.S. + human serum
of
Tumour onset Death
Days Mean Days Mean
. 6 6 6 6 15 15 15 15
. 6 6 6 6 14 16 18 16
. 6 6 6 6 16 18 20 18
. 6 6 6 6 16 17 18 17
. 8 8 13 10 21 21 28 23
. 9 9 13 10 22 24 24 23
.11 16 21 16 23 32 43 33
.13 14 15 14 25 27 28 27
Isparaginase Contained
Serum Added
Treatment given when
tumour established
AA
Death
Days Mean
. 15 16 16 16
. 15 15 16 15
. 17 18 19 18
. 14 15 16 15
. 15 16 16 16
. 18 18 20 19
. 18 18 21 19
. 17 19 20 19
A marked alteration in the pattern ofresults was seen when animals were given
1 ml. of human serum together with 300 units of l-asparaginase. The interval
between inoculation and tumour being palpable was 16 days, as compared with
6 daysinthosegivenasparaginase or serum only. Duringthe interval betweenthe
occurrence of tumour and death of the animal the rate of tumour growth in
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FIG. 4.-Tumour growth of 1 x 106 EARAD/1 cells, 0 0 given 1 ml. of Eagle's medium,
or *0* 1 ml. of human serum only.
treated animals was similar to that seen in the controls (Fig. 4, 5). A similar
pattern ofresults was seen when human serum was given with 1000 and 2000 units
of asparaginase (Table II).
When E. coli asparaginase was given at the time when the tumour was well
established, significant benefit was obtained at all dose levels. Thus in those given
Eagle's medium death occurred in 18 days, whereas those given 300, 1000 and
TABLE I.-To Compare the Anti-tumour Activity ofA
in Guinea Pig Serum Alone, or with Human
Treatment given with inoculation
tumour cells
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FIG. 5.-Tumour growth of 1 x 106 EARAD/1 cells, after administration of 300 units E. coli
asparaginase at time of inoculation, 0 - -- 0 alone, or *- 0 with 1 ml. of human
serum added.
TABLE II.-To Compare the Anti-tumour Activity of E. coli Asparaginase
Alone, and with Human Serum Added
Treatment
1 ml. Eagle's medium .
1 ml. serum
Asparaginase 300 units
Asparaginase + serum
Asparaginase 1000 units
Asparaginase + serum
Asparaginase 2000 units
Asparaginase + serum
Treatment given with inoculation of
tumour cells
Tumour onset Death
Days Mean Days Mean
. 6 6 7 6 16 19 20 18
. 6 6 8 7 16 18 18 17
. 6 6 6 6 17 19 21 19
.13 14 20 16 24 25 37 29
. 6 6 6 6 20 20 22 21
.14 20 20 18 30 32 32 31
. 8 10 10 9 22 23 24 23
.17 20 20 19 23 31 41 32
Treatment given when
tumour established
A
Death
t Ak
Days Mean
.15 18 21 18
.17 20 18 18
.22 24 25 24
.22 24 25 24
.25 27 29 27
.24 24 27 25
.27 32 38 32
.27 32 29 29
2000 units of l-asparaginase survived for 24, 27 and 32 days respectively. The
addition of human serum did not influence the rate of tumour growth, nor these
survival periods, at any dose level of asparaginase (Fig. 6, Table II).
In an attempt to define which serum fraction, if any, was responsible for the
effect seen when E. coli asparaginase plus human serum was given concurrently
with the tumour cell inoculation, experiments were set up in which the following
plasma fractions were substituted for whole serum-fibrinogen, gamma beta and
alpha globulins and albumin. These were made up to give a total protein of
7 g.%, which was the same as when whole human serum was used. All animals
given asparaginase received 300 units and it was found that all fractions tested
had a similar effect to human serum, in that both the interval to the occurrence
of tumour and death were prolonged (Table III).
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Fia. 6.-Tumour growth of 1 x 106 EARAD/L cells, after administration of 300 units E. c2 2
asparaginase on day 7, 0 --- 0 alone, or * * with 1 ml. of human serum added.
TABLE III.-To Compare the Effect of the Addition of Whole Serum and Various
Fractions to 300 Units of E. coli Asparaginase
Tumour onset Death
Treatment Days Mean Days Mean
No asparaginase . 6 6 6 6 . 18 19 19 19
Asparaginase only . . 6 6 7 6 . 17 19 20 19
Asparaginase + whole serum . 10 14 21 15 24 28 31 28
Asparaginase + fibrinogen . . 12 18 19 16 31 33 38 34
Asparaginase + y globulin . 19 20 21 20 24 31 38 31
Asparaginase + ,B globulin . 17 17 20 18 . 24 24 27 25
Asparaginase + o globulin . . 17 18 21 19 . 24 26 26 25
Asparaginase + albumin . 12 12 17 14 . 24 24 27 25
DISCUSSION
The response to l-asparaginase of the mouse leukaemia system used in these
experiments has been reported by Mashburn et al. (1967) and our results are very
similar. They also found asparaginase, as contained in extracts from E. coli,
to be much less effective ifgiven at the time ofinoculation than ifgiven some days
later when tumour growth was well established. Asparaginase, as contained in
guinea pig serum, however, is more effective ifgiven with the cells, although it will
inhibit the growth of an established tumour (Boyse et al., 1967). The difference
in the pattern of action ofthe two asparaginases has been seen with various other
mouse leukaemia systems, including the Gardner lymphosarcoma in C3H mice
(Broome, 1963). 1-Asparaginase, as obtained from different sources, varies
widely in its biological behaviour. Thus the enzymes obtained from chicken
liver, yeast, B. coagulans are ineffective, whereas those from guinea pig serum,
E. coli, Serratia marcescens and Erwinia carotovora are effective tumour inhibitors
(Ohnuma et al., 1967; Broome, 1965; Manning and Campbell, 1957; Mashburn and
Wriston, 1964; Rowley and Wriston, 1967; Wade et al., 1968).
Broome (1965, 1968b) has studied some of the factors which might influence
tumour-inhibiting capacity of asparaginase from guinea pig serum and from
E. coli, and found that the latter is more rapidly cleared from the circulation.ANTI-TUMOUR ACTIVITY OF TWO ASPARAGINASES 375
Thus 170 units ofguinea pig serum had a half life in the mouse of 11 hours, while
150 units of E. coli asparaginase had a half life of 3 hours, and the biologically
ineffective yeast enzyme was cleared in less than halfan hour. The halflife is not,
however, the only factor determining the difference in activity, as the avidity of
the enzymes for substrate at physiological levels also varies (Schwartz, Reeves
and Broome, 1966; Broome, 1968c). The importance of clearance rates has been
emphasised by the demonstration that, in mice previously infected with L.D.H.
virus, E. coli asparaginase is less rapidly cleared and its tumour inhibiting activity
is increased (Old et al., 1968; Broome, 1968c). Although we have not done
clearance rate studies we would speculate that protein, as contained in human
serum and its fractions, would cause stabilisation of the asparaginase molecule
and thus lengthen its halflife. The fact that the various plasma fractions were as
equally effective as whole serum would support the view that the action of serum
is a non-specific one, due to its protein content rather than any specific interaction
between the enzyme and the serum component.
The therapeutic value of asparaginase is not yet established, but it has great
attraction because it is the " first example ofa chemotherapeutic agent based on a
biochemical difference between the normal and malignant cells " (Lancet, 1968).
This biochemical difference can be measured in vitro, and thus one can predict
the response of any particular leukaemic patient (Sobin and Kidd, 1966; Oettgen
et al., 1968). As asparaginase is likely to be in short supply for some time, it is
important to define its optimum method ofuse. The present work would indicate
that it might be of interest to study the protein content of solutions in which
the enzyme is prepared.
SUMMARY
The effect of the addition of human serum on the anti-tumour activity of
l-asparaginase, as contained in extracts ofE. coli andguineapigserum, wasassessed
usingthe mouse leukaemia system (EARAD/1). Itwas foundthatifhumanserum
and E. coli asparaginase were given simultaneously with the inoculation of the
tumour cells, then the tumour inhibiting property of the enzyme was increased,
whereas this effect was not seen if the asparaginase and serum were given when
tumour growth was established. The addition ofhuman to guinea pig serum did
not influence its activity whether given when the tumour cells were inoculated, or
when the tumour was established.
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